Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity
Sponsor: Ascletis Pharma (China) Co., Limited
Summary
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASC30 injection
Official title: A Phase I/IIa, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASC30 Injection, for Subcutaneous Use in Participants With Obesity
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
115
Start Date
2024-09-16
Completion Date
2026-04
Last Updated
2025-12-15
Healthy Volunteers
Yes
Conditions
Interventions
ASC30 Injection, for subcutaneous use or placebo
Drug: ASC30 injection, for subcutaneous use Drug: Placebo injection, for subcutaneous use
Locations (1)
Ascletis clinical site
San Antonio, Texas, United States